燃石医学 BNR 深 沪
等待开盘 12-06 09:30:00 美东时间
20.00
-0.550
-2.68%
华盛通- 最 高21.17
- 今 开20.58
- 成交量 4.30万股
- 最 低 19.5014
- 昨 收 20.55
- 总市值 2.15亿
- 52周最高 23.59
- 市盈率 静 --
- 换手率 0.40%
- 52周最低 2.18
- 委 比 87.13%
- 总股本 1076.66万
- 历史最高 397.50
- 量 比 0.59
- 振 幅 8.12%
- 历史最低 2.18
- 每 手 1
- 风险率 3.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Burning Rock Announces 2025 Annual General Meeting to be Held on December 23, 2025
Burning Rock Biotech Limited will hold its 2025 annual general meeting on December 23 at its Shanghai office. The meeting will address three proposals: ratifying Ernst & Young Hua Ming LLP as auditor, re-electing Feng Deng and Licen Lisa Xu as directors, and authorizing directors to take necessary actions. Shareholders and ADS holders are encouraged to vote in favor. The record date is December 1, and voting instructions are available online. The...
12-01 09:11
中概股周涨跌榜 | 智驾概念股爆发！禾赛、小马智行周内集体涨超20%
Amber International Holding涨84.6%；燃石医学涨51.5%；Texxon Holding涨49.6%
11-29 16:15
Burning Rock Biotech’s Q3 2025 Financial Highlights
Burning Rock Biotech Ltd. ( ($BNR) ) has released its Q3 earnings. Here is a br...
11-21 12:05
Earnings Scheduled For November 20, 2025
Companies Reporting Before The Bell • Atkore (NYSE:ATKR) is likely to report qu...
11-20 19:11
Burning Rock Biotech Q3 EPS $(0.20) Up From $(0.50) YoY, Sales $18.488M Up From $18.331M YoY
Burning Rock Biotech (NASDAQ:BNR) reported quarterly losses of $(0.20) per share. This is a 60 percent increase over losses of $(0.50) per share from the same period last year. The company reported $18.488 million in
11-20 15:32
燃石医学(BNR.US)：2个月横盘终迎“五连阳”，股价累涨逾60%背后盈利预期成关键
结合燃石25Q2的盈利情况来看，在控费策略下，公司25Q2的归普净亏损仅剩970万元，同比大幅收窄91%。若保持目前的净亏损收窄趋势，燃石最终实现扭亏或近在眼前。
10-28 13:47
华大智造测序平台助力！燃石医学乳腺癌伴随诊断试剂盒在日本获批上市
2025年9月24日，广州燃石医学检验所有限公司（纳斯达克：BNR，燃石医学）和日本Riken Genesis Co., Ltd. (Riken Genesi...
09-25 04:28
Burning Rock's OncoGuide™ OncoScreen™ Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer
Riken Genesis and Burning Rock Biotech have received approval from Japan's Ministry of Health, Labour and Welfare for their OncoGuide™ OncoScreen™ Plus CDx System, which will serve as a companion diagnostic for AstraZeneca's capivasertib. This system, combining a diagnostic kit and analysis program for use with next-generation sequencing, identifies alterations in PIK3CA, AKT1, and PTEN genes. It aims to guide treatment decisions for adult patien...
09-24 06:42
